Spotlight

UCL shortlisted for the Times Higher Education Entrepreneurial University of the Year Award

UCL has been shortlisted for the Times Higher Education Entrepreneurial University of the Year Award.

The Award, which is sponsored by the National Centre for Entrepreneurship Education, seeks to recognise an institution which has developed an unparalleled environment for fostering enterprise throughout its staff and students and delivered significant impact in its local community, across the UK and overseas.

Read full article



follow us on twitter


Professor Stephen Caddick

VICE-PROVOST (ENTERPRISE AND LONDON)

T: +44 (0)20 7679 7538
E: VPEnterprise@ucl.ac.uk

Stephen Caddick

UCL Enterprise is led by the Vice-Provost (Enterprise), Professor Stephen Caddick. The Office of the Vice-Provost (Enterprise) is responsible for delivering UCL’s Enterprise agenda with the greatest economic and societal impact. The Vice-Provosts are members of the Provost's senior management team.

“Enterprise is important to all universities, but resonates particularly with UCL. From our inception we were created as an enterprising institution, with a bold ambition to create a University dedicated to the greatest good for the greatest number. There are outstanding opportunities for us to work with all academic departments and divisions to help enrich the core academic mission of teaching and research and to identify innovative ways of engagement with the wider world. An enterprising community is one that is resourceful, creative, dynamic, and bold – characteristics that we recognise as part of the fabric of UCL.”
Professor Stephen Caddick, Vice-Provost (Enterprise and London)

Professor Stephen Caddick was appointed as Vice-Provost (Enterprise) in 2010. He joined UCL in 2003 as Vernon Professor of Organic Chemistry and Chemical Biology. He was the founding director of the Centre for Chemical Biology, and Head of the Department of Chemistry. He maintains an active academic research career, has many external roles and is co-founder of Thiologics, a spin-out company dedicated to developing new biological therapeutics.